Impact Of Dexamethasone On COVID-19 Patients

Abstract

The coronavirus infection 19 (COVID-19) is an extremely contagious as well as infectious agent’s viral illness generated by the extreme acute respiratory disorder coronavirus which called (SARS-CoV-2) virus, which first appeared in Wuhan as well as China, and has since spread throughout the world.  The 2019 Coronavirus Infection (COVID-19) is linked to diffuse lung injury.  Corticosteroids can help to prevent respiratory damage as well as death by modulating inflammation injury occurs in the lung. The method of this study is based on an analysis of past studies' literature; the aim of a literature review is to obtain a knowledge of current studies as well as debates related to this specific research subject, as well as to address that information in the form of a research. The objectives of this research were to look at the anti-inflammatory effects of corticosteroids (particularly dexamethasone) in individuals with COVID-19-induced moderate-to-severe ARDS.

It also described the pathway of glucocorticoid metabolic effects as well as illustrated some adverse effects of dexamethasone on various organs in COVID-19 patients. According to the findings, small quantities of corticosteroids (dexamethasone) can minimize mortality in patients with serious COVID-19 disorder, but they have no effect on the death rate in patients with such a mild type of the illness. Patients with moderate symptoms should avoid dexamethasone. Further randomized clinical trials on this treatment are required to further develop our knowledge of the variables as well as effect of glucocorticoids on people with SARSCoV-2 disease.